Asthma and lower airway diseaseTest for Respiratory and Asthma Control in Kids (TRACK): A caregiver-completed questionnaire for preschool-aged children
Section snippets
Draft questionnaire development
Development of the draft questionnaire was based on input from a working group, caregiver and physician interviews, and subsequent qualitative research (see the Methods section in this article's Online Repository at www.jacionline.org). Items for the draft questionnaire were based on content generated from 2 focus groups, each consisting of 8 primary caregivers of preschool-aged children with recurring respiratory problems or asthma. Physical signs of respiratory problems most often reported
Total sample
Characteristics of the total sample (N = 486) of caregivers who completed the draft 33-item questionnaire and their children are provided in Table I. Most caregivers were younger than 45 years of age (95.7%), female (88.9%), and white (71.8%). Most children were aged 3 to 5 years (82.1%); had 1 or more episodes of wheezing, coughing, or shortness of breath in the past 4 weeks (61.9%); and had symptoms that were either not well controlled or very poorly controlled (73.7%). Most (61.9%) children
Discussion
The objective of this study was to develop an instrument to measure respiratory and asthma control in preschool-aged children with symptoms consistent with asthma that included the impairment and risk domains of control recommended by the most recent NAEPP guidelines.12 Regular assessment and monitoring of respiratory symptoms and activity limitations are essential in the care of asthma. However, standardized methods for measuring control in clinical settings are not available for
References (24)
- et al.
Trends in the cost of illness for asthma in the United States, 1985–1994
J Allergy Clin Immunol
(2000) - et al.
The health economics of asthma and rhinitis. I. Assessing the economic impact
J Allergy Clin Immunol
(2001) - et al.
Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys
J Allergy Clin Immunol
(2004) - et al.
A potential pitfall in provider assessments of the quality of asthma control
Ambul Pediatr
(2003) - et al.
Development and cross-sectional validation of the Childhood Asthma Control Test
J Allergy Clin Immunol
(2007) - et al.
Development of the asthma control test: a survey for assessing asthma control
J Allergy Clin Immunol
(2004) - et al.
Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists
J Allergy Clin Immunol
(2006) - et al.
Surveillance for asthma—United States, 1980-1999
MMWR Surveill Summ
(2002) Centers for Disease Control and Prevention. Asthma prevalence and control characteristics by race/ethnicity—United States, 2002
MMWR Morb Mortal Wkly Rep
(2004)Centers for Disease Control and Prevention. Asthma mortality and hospitalization among children and young adults: United States, 1980-1993
JAMA
(1996)
Prevalence, impact, and trends in childhood disability due to asthma
Arch Pediatr Adolesc Med
Asthma in the United States: recent trends and current status
J Manag Care Pharm
Cited by (121)
Dysfunctional neutrophil type 1 interferon responses in preschool children with recurrent wheezing and IL-4–mediated aeroallergen sensitization
2024, Journal of Allergy and Clinical Immunology: GlobalCorrelation between impulse oscillometry parameters and test for respiratory and asthma control in kids (TRACK) in asthma control of preschoolers with asthma
2024, Journal of the Formosan Medical AssociationHealth-Related Quality of Life for Parents of Infants with Bronchopulmonary Dysplasia
2024, Journal of PediatricsFunctional immunophenotyping of blood neutrophils identifies novel endotypes of viral response in preschool children with recurrent wheezing
2023, Journal of Allergy and Clinical ImmunologyThe Asthma Impairment and Risk Questionnaire enhances the assessment of asthma control
2023, Annals of Allergy, Asthma and ImmunologySocial determinants of health influence preschool and caregiver experiences during symptoms and exacerbations of wheezing
2023, Annals of Allergy, Asthma and Immunology
Supported by AstraZeneca LP.
Disclosure of potential conflict of interest: K. R. Murphy has received consulting honoraria from AstraZeneca, Schering-Plough, Merck, and Dey and has received research support from AstraZeneca, GlaxoSmithKline, Merck, Schering-Plough, and Novartis. R. S. Zeiger has served as a consultant for AstraZeneca. B. Chipps has received research support from Aventis, Genentech, AstraZeneca, GlaxoSmithKline, Novartis, Schering-Plough, Sepracor, and Merck; has received grants for educational activites from Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, and Novartis; has served as an advisor for Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, MedPoint, Novartis, Schering-Plough, Sepracor, and Merck; and has served on the speakers' bureau for Alcon, Aventis, Genentech, AstraZeneca, Boehringer, GlaxoSmithKline, MedPoint, Novartis, Pfizer, Schering-Plough, Sepracor, and Merck. M. Mellon has served as a consultant for AstraZeneca and has served as a speaker for AstraZeneca and Schering-Plough. K. Lampl is employed by AstraZeneca.